清除微小残留病可改善慢性淋巴细胞白血病患者的总生存和无进展生存:NCRN CLL207 二期试验评估阿仑单抗巩固治疗
该项二期试验评估化疗后持续低水平可检测病灶的应答者接受阿仑单抗巩固治疗。47例接受巩固治疗,39例(83%)在巩固治疗结束时实现血液和骨髓微小残留病清除,18例(38%)6个月后血液仍微小残留病阴性。6个月时微小残留病阴性者5年无进展生存和总生存显著优于微小残留病阳性者。
要点
- 47例接受阿仑单抗巩固治疗,39例(83%)巩固结束时血液和骨髓微小残留病清除。
- 18例(38%)6个月后血液仍微小残留病阴性,中位至微小残留病复发时间46个月。
- 6个月时微小残留病阴性者5年无进展生存78% vs 39%(P=0.010),总生存89% vs 64%(P=0.029)。
核心结论
- 清除微小残留病可改善慢性淋巴细胞白血病患者的总生存和无进展生存。
研究设计与样本
- 二期试验评估化疗后持续低水平可检测病灶的应答者接受阿仑单抗巩固治疗。
- 化疗后6-24个月采用多参数流式细胞术筛查血液微小残留病。
- 微小残留病阳性者接受阿仑单抗30 mg皮下注射每周3次共6周。
主要发现
- 47例接受阿仑单抗巩固治疗。
- 17例(36%)报告22起严重不良事件中的19起与阿仑单抗相关,并发生1例死亡。
- 39例(83%)在巩固治疗结束时实现血液和骨髓微小残留病清除。
- 18例(38%)在6个月后血液仍微小残留病阴性。
- 18例6个月时微小残留病阴性者中位至微小残留病复发时间46个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With immunochemotherapy, remission duration and survival in patients with chronic lymphocytic leukaemia is dependent on the level of minimal residual disease (MRD) after treatment. This phase II trial assessed alemtuzumab consolidation post-chemotherapy in patients who responded with persistent low levels of detectable disease. Blood was screened for MRD using multi-parameter flow cytometry, 6-24 months post-chemotherapy. MRD-positive participants received alemtuzumab 30 mg subcutaneously 3 times weekly for 6 weeks. Following a marrow assessment, MRD-negative participants or non-responders stopped therapy and MRD-positive participants with 1 + log reduction had 6 more weeks of alemtuzumab. Alemtuzumab consolidation was received by 47 participants. One death and 19 of 22 serious adverse events reported from 17 (36%) participants were alemtuzumab-related. MRD eradication from blood and bone marrow was achieved in 39 (83%) participants at the end of consolidation, with 18 (38%) remaining MRD-negative in the blood 6 months later. Of the 18 participants who were MRD-negative at 6 months, the median time to MRD relapse was 46 months, which was similar to patients who were MRD-negative at baseline and were followed up. The 5-year progression-free survival (PFS) and overall survival (OS) of participants who were MRD-negative at 6 months was significantly better than MRD-positive participants [PFS: 78% vs. 39% (P = 0·010), OS: 89% vs. 64% (P = 0·029)].
引用
- Varghese AM, Howard DR, Pocock C, et al. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. Br J Haematol. 2016. PMID: 28032335. doi:10.1111/bjh.14342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。